医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Dr. Reddy’s Q3 and 9M FY17 Financial Results

2017年02月04日 PM11:52
このエントリーをはてなブックマークに追加


 

HYDERABAD, India

Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY) today announced its consolidated financial results for the third quarter and nine months ended December 31, 2016 under International Financial Reporting Standards (IFRS).

Q3 FY17: Key Highlights

  • Revenues at Rs. 37.1 billion: QoQ growth: 3%

    • YoY decline: 7%
  • Gross Profit Margin at 59.1%.
  • Research & Development (R&D) spend at Rs. 5.0 billion. [13.4% of Revenues]
  • Selling, general & administrative (SG&A) expenses at Rs. 11.3 billion [YoY decline: 6%]
  • EBITDA at Rs. 8.8 billion [23.7% of Revenues]
  • Profit after tax at Rs. 4.7 billion [12.7% of Revenues]

9M FY17: Key Highlights

  • Revenues at Rs. 105.3 billion: YoY decline: 10%
  • Gross Profit Margin at 57.2%.
  • Research & Development (R&D) spend at Rs. 15.0 billion. [14.2% of Revenues]
  • Selling, general & administrative (SG&A) expenses at Rs. 35.4 billion [YoY increase: 4%]
  • EBITDA at Rs. 19.2 billion [18.2% of Revenues]
  • Profit after tax at Rs. 8.9 billion [8.5% of Revenues]

Commenting on the results, Co-chairman and CEO, G V Prasad said “Our performance in Q3 has delivered a modest sequential revenue growth of 3% over the previous quarter. Our EBITDA has improved significantly from the last quarter to Rs. 8.8 billion, on the back of enhanced emphasis on operational efficiencies and controlling of SG&A costs across all our businesses.

All amounts in millions, except EPS

       

All US dollar amounts based on convenience translation rate of I USD = Rs. 67.92

     

Dr. Reddy’s Laboratories Limited and Subsidiaries

Consolidated Income Statement

 
Particulars Q3 FY17 Q3 FY16 Growth %
  ($)   (Rs.)   %   ($)   (Rs.)   %  
Revenue 546   37,065   100.0 584   39,679   100.0 (7)
Cost of revenues   223   15,166   40.9   237   16,089   40.5   (6)
Gross profit   322   21,899   59.1   347   23,590   59.5   (7)
Operating Expenses
Selling, general & administrative expenses 167 11,341 30.6 177 12,039 30.3 (6)
Research and development expenses 73 4,956 13.4 60 4,095 10.3 21
Other operating income   (3)   (187)   (0.5)   (2)   (122)   (0.3)   53
Results from operating activities   85   5,789   15.6   112   7,578   19.1   (24)
Net finance (income) / expense (1) (44) (0.1) 1 62 0.2 171
Share of profit of equity accounted investees   (1)   (89)   (0.2)   (1)   (64)   (0.2)   38
Profit before income tax   87   5,922   16.0   112   7,580   19.1   (22)
Income tax expense   18   1,221   3.3   26   1,788   4.5   (32)
Profit for the period   69   4,701   12.7   85   5,792   14.6   (19)
       

         

       
Diluted EPS   0.42   28.32       0.50   33.86       (16)
 
   

EBITDA Computation

 
Particulars Q3 FY 17   Q3 FY 16
  $   Rs.   $   Rs.
Profit before income tax 87   5,922 112   7,580
Interest income, net* (1) (53) (3) (236)
Depreciation 29 1,936 25 1,685
Amortization / Impairment   15   988   16   1086
EBITDA   129   8,793   149   10,115
EBITDA% to Revenues       23.7%       25.5%

* Includes income from Investments

 
   

Key Balance Sheet Items

 
Particulars As on 31st Dec 16   As on 30th Sep 16
  ($)   (Rs.)   ($)   (Rs.)
Cash and cash equivalents and Other current Investments   297   20,145   315   21,379
Trade Receivables   605   41,119   544   36,939
Inventories   442   30,052   420   28,516
Property, plant and equipment   842   57,209   825   56,052
Goodwill and Other Intangible assets   736   49,977   747   50,766
Loans and borrowings (current & non-current)   854   57,999   890   60,480
Trade & other payables   196   13,308   181   12,281
Equity   1,782   121,040   1,697   115,264
   

All amounts in millions, except EPS

       

All US dollar amounts based on convenience translation rate of I USD = Rs. 67.92

     

Revenue Mix by Segment [Year on year]

 
Particulars Q3 FY17   Q3 FY16 Growth %
  ($)   (Rs.)   %   ($)   (Rs.)   %  
Global Generics   451   30,638   83   494   33,558   84   -9
North America       16,595           19,417       -15
Europe*       2,148           1,937       11
India       5,947           5,805       2
Emerging Markets#       5,948           6,399       -7
PSAI   80   5,400   14   75   5,082   13   6
North America       1,259           1,037       21
Europe       1,828           1,951       -6
India       409           622       -34
Rest of World       1,904           1,472       29
Proprietary Products & Others   15   1,027   3   15   1,039   3   -1
Total   546   37,065   100   584   39,679   100   -7
       
     

Revenue Mix by Segment [Sequential]

 
Particulars Q3 FY 17 Q2 FY 17 Growth %
  ($)   (Rs.)   %   ($)   (Rs.)   %  
Global Generics   451   30,638   83   427   28,995   81   6
North America       16,595           16,134       3
Europe*       2,148           1,776       21
India       5,9

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Konica Minolta and Innovation Network Corporation of Japan Close Acquisition of Ambry Genetics
  • Median Technologies Appoints Vivian Wang as General Manager, China and Takashi Hayashi as Managing Director, Japan
  • Second Sight Announces Appointments of Frank Vandeputte as Vice President and General Manager, EMEA and Asia Pacific; Gregoire Cosendai as Vice President, Clinical Affairs
  • 武田薬品がALK陽性非小細胞肺がんでのALUNBRIGTM(ブリガチニブ)のピボタル第2相ALTA試験の最新データを発表
  • Shinkowa Pharmaceutical Co., Ltd., Distributor of the World’s First Supplements Containing β-Nicotinamide Mononucleotide (NMN), Has Begun World-Wide Distribution of the Special Products “NMN PURE 3000″ and “NMN PURE 1500″